GSK and Shionogi have announced an agreement with Pfizer to restructure the shareholding of ViiV Healthcare, a company focused on HIV treatments, according to Forbes. Under the transaction, Pfizer will receive USD 1.875 billion, while its 11.7% stake will be acquired by Shionogi.
Following completion, Shionogi will increase its ownership in ViiV Healthcare to 21.7%, while GSK will retain a majority stake of 78.3%. Shionogi’s representation on ViiV’s board will continue through a single director, currently held by John Keller.
Ownership simplification and strategic focus
Read also: GSK to acquire RAPT Therapeutics in USD 2.2 billion deal, enters food allergy space
Under the terms of the agreement, ViiV Healthcare will issue new shares to Shionogi in exchange for a USD 2.125 billion investment and will cancel Pfizer’s existing stake. The companies stated that the transaction aims to simplify ViiV Healthcare’s ownership structure and strengthen the partnership between GSK and Shionogi in the development and prevention of HIV treatments.
Founded in 2009, ViiV Healthcare develops innovative medicines, including long-acting injectable therapies for HIV. The transaction remains subject to regulatory approvals in relevant markets and is expected to close in the first quarter of 2026.
Photo: Pfizer
UK
IT
ES
DE
FR
RO
PT
HU
